Thierry Bernard: I think, Doug, Roland alluded to that during the presentation in his part. There is softness on the life science market, not just for QIAGEN. If you look at competition, I believe that we outperform competition and competition results in terms of growth. And there is more dynamism at the moment on the clinical market. The softness in life science mainly translates into cautiousness on capital expense. And as we have explained, for us, it was planned, we did even better than what we expected on Q1. We did better than the competition that have reported the results, at least those that are completely comparable to QIAGEN. And as we said and Roland as well, we reaffirm our guidance. So we see quite solid improvement. This is where we are at the moment.
Douglas Schenkel: Okay, thank you again.
Operator: We’ll take our last question from Dan Brennan with TD Cowen. Please go ahead.
Daniel Brennan: Great. Thank you. Maybe first one, just on PCR amplification. I know there was a question earlier on the digital PCR portfolio. But after the 12% decline in 1Q, I know the press release says you expect the business to improve through the year. What’s assumed for the base business ex digital PCR and kind of what drives that improvement as you see it progress through the year?
Thierry Bernard: Because we have such a wide portfolio in PCR, I’m not talking digital PCR, which is made of older technologies, newer applications that overall, we believe that the trend will follow the market trend in our sequential improvement expectation. So do not forget that we have a significant installed base also, which is driving this assumption. So this is confirming what we have said. But again, Dan, clearly, in PCR because we focus and because this is also a symbol of that new QIAGEN for the last years, the efforts in R&D, the efforts in presence on the ground, marketing and sales will not go overall for the PCR portfolio. It will go to the digital PCR portfolio because this is where we can really take a #1 or — #1 position on the market. So that’s the allocation of priorities. And this is what you will see also clearly on June 17.
Daniel Brennan: Maybe related to that, is it reasonable to think you’ll roll out kind of new multiyear growth and/or margin targets in June? And kind of can you step back? And what are the goals for the Investor Day?
Thierry Bernard: I think the John and Roland can chime in as well. The goal for the Investor Day is to go on the ambitions top line and also bottom line for the coming four years is to show why we do believe that we have significant growth drivers in our portfolio, and we will show clear numbers here. But we also believe that QIAGEN needs to accelerate on improving profitability, and we want also to show with what kind of efficiency measures we want to achieve that. And obviously, it’s also an opportunity for you guys to meet also part of the new management of QIAGEN. You know that we have brought different new manager at the Executive Committee, a new Head of Operations, a new Head for Life Science, a new Head for Clinical Diagnostics. And you will see also those last two ones, Head of Life Science and Clinical Diagnostics on stage and giving their also assumptions for the growth of their respective portfolio.
Daniel Brennan: Terrific. Thank you.
John Gilardi: Thank you, Thierry, on that point. Again, we look forward to seeing you on June 17 in New York at our event. And if you have any questions or comments in the meantime. Please do not hesitate to reach out to us. And thank you again for your interest in QIAGEN. Bye-bye.
Operator: Ladies and gentlemen, this concludes the conference call. Thank you for joining, and have a pleasant day. Goodbye.
